Professor of Biomedical Engineering and Medical Genetics
University of British Columbia, Canada
Dr. Kelly McNagny is currently a full professor in the departments of Biomedical Engineering and Medical Geneticsobtained a BSc in Biology and Biotechnology at Worcester Polytechnic Institute, Massachusetts and subsequently a PhD in Cellular Immunology at the U of Alabama at Birmingham (UAB). At UAB he worked with Dr. Max D Cooper, a founding father of B cell immunology, and his research focused on cell surface proteins that regulate B cell maturation and homing. He then moved to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany where he performed postdoctoral studies with Dr. Thomas Graf and his work focused on transcriptional control of stem cell fate and the commitment to macrophage, eosinophil and thrombocyte development. He also identified a number of novel hematopoietic stem cell surface proteins (the CD34 family) and this then became the research focus of his own laboratory at The Biomedical Research Centre, at the University of British Columbia in Vancouver. His work focuses on stem cell behavior, innate immune responses, inflammatory disease, cancer biology and immunotherapeutics. His research relies heavily on the use of transgenic mice and animal models of human inflammatory disease as well as high-throughput “omics” technologies to reveal the immune components that determine the outcome of human disease. Nationally, he has filled leadership roles in the Stem Cell Network Centre of Excellence, the Centre for Drug Research and Development and the AllerGen Network Centre of Excellence. He is currently Co-leader of the Immunotherapeutics Cluster at UBC and is UBCs Delegate to CIHR.
